statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's...

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties Moleculin Announces Presentation of Positive Data Demonstrating...

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX - Free Report) in a report released on Friday morning. The firm issued a sell rating on the stock.
A number of other...

Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com

Moleculin Biotech, Inc. (NASDAQ:MBRX - Get Free Report)'s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $7.63 and traded as...

Moleculin Biotech (NASDAQ:MBRX) Share Price Passes Below 50-Day Moving Average of $7.63

Equities researchers at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX - Get Free Report) in a research note issued to investors on Thursday. The firm set a "sell" rating...

Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX  Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the...

Moleculin Biotech, Inc. (NASDAQ:MBRX  Free Report)  Research analysts at Roth Capital decreased their Q1 2024 earnings per share estimates for Moleculin Biotech in a research report...

Roth Capital Comments on Moleculin Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:MBRX)

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference PR Newswire HOUSTON, March 28, 2024 Live webcast...

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity PR Newswire HOUSTON...

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML PR Newswire...

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Volume	16,771.00
52-Wk High	$15.75
52-Wk Low	$4.28

MBRX Moleculin Biotech Inc

About

Feed

News

Sentiment

Fundamentals